新疆银朵兰药业

Xinjiang Yindolan Pharmaceutical is a prominent high-tech pharmaceutical company in China specializing in the modernization and production of Traditional Uyghur Medicine (TUM). As a subsidiary of Xinjiang Huayuan Investment Group, the company operates a comprehensive industrial chain that includes standardized medicinal herb cultivation, research and development, and GMP-certified manufacturing. Its flagship product, Compound Yizhihao Granules, is a widely recognized anti-viral and anti-inflammatory treatment that has been included in national and regional medical insurance catalogs and COVID-19 treatment protocols. The company focuses on respiratory, urological, and gynecological health, leveraging the unique botanical resources of the Xinjiang region. Yindolan is recognized as a national industrialization base for ethnic medicine and continues to invest in clinical evidence-based research to bring traditional therapies to the modern global market.